Advanced NanoTherapies

Executive Summary

Advanced NanoTherapies (A.N.T.) is a private, clinical-stage medical device company pioneering a next-generation drug-coated balloon (DCB) platform powered by proprietary nanoparticle technology. Its lead product, SirPlux™ Duo, is a dual-drug (Sirolimus and Paclitaxel) coated balloon designed to treat coronary and peripheral artery disease, offering stent-like efficacy without a permanent implant. The company's nanoparticle delivery system enables controlled, sustained drug release, potentially improving clinical outcomes in challenging vascular lesions. Founded in 2018 and headquartered in San Diego, A.N.T. has secured FDA Breakthrough Device Designation for its below-the-knee (BTK) indication, underscoring the unmet need and innovation potential. The company is now preparing to initiate its first-in-human (FIH) clinical trial, a critical milestone that will validate the safety and preliminary efficacy of the SirPlux Duo balloon in patients with peripheral artery disease. With a strong intellectual property portfolio and a differentiated approach to localized drug delivery, Advanced NanoTherapies is poised to address limitations of current DCBs, including inconsistent drug transfer and restenosis rates. Successful clinical translation could position the company as a leader in the vascular intervention space, offering an alternative to permanent stents and improving patient outcomes in coronary and peripheral applications.

Upcoming Catalysts (preview)

• Q4 2026FDA IDE Approval for First-in-Human Trial80% success
• Q1 2027First Patient Enrolled in SirPlux Duo FIH Trial70% success